Product
Supplier
Encyclopedia
Inquiry
API Orforglipron buy - large image1
API Orforglipron buy - image1

API Orforglipron

28 Inquiries

Unit Price: Get Latest Price
CAS No.:

2212020-52-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shanghai

Brand:

Hyper Chem

Packaging:

20kg/Drum 25kg/Drum

Sample Available:

Yes

Price valid (until):

2025-09-27

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Name

    Orforglipron

    CAS number

    2212020-52-3

    Description

    Orforglipron (LY3502970, OWL-833) is an orally bioavailable, non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist. It has demonstrated potent agonist activity at the human GLP-1R, with an EC₅₀ in the low nanomolar range (~0.5–1 nM) in cAMP accumulation assays in HEK293 cells expressing GLP-1R. In clinical studies, Orforglipron significantly reduced body weight and fasting plasma glucose levels in a dose-dependent manner. Additionally, it showed favorable pharmacokinetics, with a half-life supportive of once-daily dosing and no need for injection, distinguishing it from peptide-based GLP-1 agonists.

    Related CAS

    2212020-52-3 (free) 2415797-61-2 (calcium) 2212021-26-4 (calcium hydrate)

    Synonym

    LY3502970; LY 3502970; LY-3502970; OWL833; OWL 833; OWL-833; Orforglipron;

    Appearance

    Solid powder

    Quality Standard

    USP, EP, BP, CP

    Shipping Condition

    Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

    Storage Condition

    Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

    Shelf Life

    >2 years if stored properly

    Sample package

    Aluminium foil bag

    Commercial package

    Aluminium Tin, Fiber drum

    Origin

    China


    Orforglipron More Info

    Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist, mainly developed for treating type 2 diabetes mellitus (T2DM) and chronic weight management in adults with obesity/overweight (plus weight-related comorbidities like hypertension). Its oral form is a key edge over injectable GLP-1 RAs, boosting patient adherence.

    Mechanism of Action

    It activates GLP-1 receptors (in pancreas, brain, gut, etc.):

    Blood glucose control: Stimulates glucose-dependent insulin secretion (lowering hypoglycemia risk) and inhibits glucagon, reducing fasting/postprandial blood glucose.

    Weight management: Acts on brain appetite centers to cut hunger and boost satiety; slows gastric emptying to prolong fullness.

    Key Indications (as of May 2024)

    T2DM: Tested for glycemic control (alone or with other drugs like metformin), reducing HbA1c in trials.

    Weight management: Studied for weight loss in obese (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) adults; shows meaningful weight loss with lifestyle changes.

    It’s in late-stage Phase 3 trials, not fully approved by FDA/EMA yet.

    Pharmacokinetics

    Resists digestive enzyme breakdown for oral absorption (lower bioavailability than injectables, but therapeutic).

    24–36-hour half-life, allowing once-daily dosing.

    Metabolized in liver, excreted in feces/urine; low drug-drug interaction risk.

    Safety

    Common mild/moderate GI issues (nausea, diarrhea) – transient, eased by low starting doses.

    Rare risks: Hypoglycemia (more with insulin/sulfonylureas), pancreatitis, gallstones.

    Contraindicated in hypersensitivity or history of acute pancreatitis; cautious use in severe renal impairment/gallbladder disease.

    Outlook

    Its oral form addresses unmet patient needs (avoiding injections). If approved, it may become a first-line option. Future research may explore more uses.

    Shop API Orforglipron-Detailed Image 1

    ECHEMI Editorial Reference
    Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is  GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
    Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

    Basic Info
    Product Name:

    Orforglipron

    Other Name:

    1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron(LY3502970);LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833

    CAS No.:

    2212020-52-3

    Molecular Formula:

    C48H48F2N10O5

    InChIKeys:

    USUWIEBBBWHKNI-BBGRWQLENA-N

    Molecular Weight:

    882.97

    EC Number:

    278-636-5

    Color/Form:

    Off-white to light yellow

    Characteristics
    Density:

    1.50±0.1 g/cm3(Predicted)

    PKA:

    7.33±0.20(Predicted)

    Critical Temperature & Pressure:

    Store at -20°C

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Pharmaceuticals,Peptide,Cosmetics,Nutritional Supplements

    Location:

    Rm. 803, Tower 4, LOFT49 Creative City Pioneer Zone, No.88 Jiru Rd. Gongshu Dist., Hangzhou, 310015 ZJ, China

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    10 days

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    11-50

    Year of Establishment:

    2013

    Company Certificates
    • Hangzhou Hyper Chemicals LimitedCertification Report by Bureau Veritas Certification Report by Bureau Veritas
    About HyperChem

    Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to meet the needs of a diverse range of pharmaceutical cosmetics ingredients and nootropic supplements companies worldwide.

    Our Competitiveness

    One-stop supply

    Wide Range Of products including pharmaceutical, Cosmetic Ingredients and nootropic supplements

    Among all the pharmaceuticals,

    90% of them with GMP certificates,

    85% of them with DMF files and

    50% of them passed FDA approval,

    30% get CEP certificate

    20% are new R&D products.

    Custom Repackaging Service


    We can efficiently repackage your material into sample sizes, custom batch-specific sizes, or semi-bulk package sizes according to your specifications. And ensures the product is packaged in a quality-controlled environment and will maintain its integrity throughout every stage of the process.

    Quality Control/Quality Assurance


    HyperChem is committed to delivering on its promises of top-quality products with verified quality data.

    All materials are vigorously inspected by the factory and/or outsourced analytical laboratories to ensure each and every lot meets or exceeds our reference standards.

    Trade assurance service with 100% payment protection, It is best achieved by delivering products and services 100% right the first time, on time, every time.

    Professional

    Transparent Communication

    Fast Reaction,

    Professional Suggestion

    Beyond Expectation.

    We have exclusive partnerships with research and production facilities across the country and we offer varied pharmaceutical services in the most cost-efficient way. The production facilities are GMP, WHO-GMP, EU GMP and US FDA approved and are backed by strong regulatory support such as Dossier, DMF, Tech Pack and relevant Stability studies for regulatory filings.

  • Inquiry History
    28 Inquiries
    Country Product Purchase Quantity Date Posted
    Bulgaria

    orforglipron

    1 KG Aug 27, 2025
    Austria

    Orforglipron

    1000 MT Jun 12, 2026
    Switzerland

    Orforglipron

    10 MG Apr 25, 2026
    United States

    Orforglipron

    20 G Apr 3, 2026
    United States

    Orforglipron

    10 G Mar 29, 2026
    United States

    oforglipron

    3 KG Jul 4, 2025
    Switzerland

    Orforglipron

    100 G Sep 25, 2026
    India

    orforglipron

    1.00 G Jul 16, 2026
    United States

    orforglipron

    10 G Apr 20, 2026
    United States

    Orforglipron

    10 G Apr 6, 2026
    United States

    orforglipron

    1 G Mar 24, 2026
    Germany

    Orforglipron

    2 G Mar 23, 2026
    Bangladesh

    Orforglipron

    500.00 KG Mar 9, 2026
    United States

    Orforglipron

    10 G Feb 28, 2026
    United Kingdom

    Orforglpron

    50 G Feb 12, 2026
    United States

    orforglipron

    1 KG Feb 6, 2026
    Lithuania

    Orforglipron

    6 G Jan 23, 2026
    China

    Orforglipron

    50 KG Nov 10, 2025
    United Kingdom

    Orforglipron

    1 G Jul 9, 2026
    Belgium

    Orforglipron

    1 G Jun 14, 2026
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.